<DOC>
	<DOCNO>NCT00370045</DOCNO>
	<brief_summary>The purpose study compare level clot formation ( platelet aggregation ) , marker heart muscle damage , inflammation two group undergo percutaneous coronary stent implantation . The first group regimen high-dose clopidogrel use combination bivalirudin plus eptifibatide , second group regimen high-dose clopidogrel bivalirudin alone . Clinical outcome determine one year enrollment .</brief_summary>
	<brief_title>Peri-Procedural Myocardial Infarction , Platelet Reactivity , Thrombin Generation , Clot Strength : Differential Effects Eptifibatide + Bivalirudin Versus Bivalirudin</brief_title>
	<detailed_description>Percutaneous stent implantation revolutionize revascularization procedure patient obstructive coronary disease angina . The major risk coronary stenting , procedure , clot formation ( thrombosis ) often lead significant heart muscle damage . The standard medical practice patient undergo coronary stenting use antiplatelet ( plavix , aspirin ) anticoagulant ( blood thinner ) therapy . The result recently complete CLEAR PLATELETS I study show addition eptifibatide ( potent antiplatelet agent ) current therapy result superior reduction clot formation , inflammation heart damage elective coronary intervention . Recent study also suggest drug bivalirudin safer effective therapy compare heparin , current anticoagulant agent choice . It hypothesize bivalirudin act anticoagulant also antiplatelet agent , make use eptifibatide current coronary therapy unwarranted . In CLEAR PLATELET II study , compare level clot formation ( platelet aggregation ) , marker heart muscle damage , inflammation two group . The first group regimen high-dose clopidogrel use combination bivalirudin plus eptifibatide , second group regimen high-dose clopidogrel bivalirudin alone . The antiplatelet/antithrombotic effect bivalirudin combination current therapy unknown ; therefore hope see effect bivalirudin arrest platelet formation without eptifibatide . This research do Sinai Hospital Baltimore Paul Gurbel M.D . principal investigator . It include 200 patient randomize equally group . Clopidogrel ( 600 mg ) + eptifibatide + bivalirudin Clopidogrel ( 600 mg ) + bivalirudin All patient receive treatment clopidogrel cath lab immediately successful stenting . All patient post-stenting receive standard antiplatelet treatment ( 75mg Plavix 325 mg aspirin ) . Patients serial assessment platelet reactivity , myocardial necrosis marker , inflammatory marker ( 3 tablespoon blood per time point ) baseline , 2 hour , 8 hour , 18- 24 hour post-stenting . All blood work process Sinai Center Thrombosis Research . Clinical outcome record use standard case report form . Patients follow 30 day 1 year telephone assess adverse event .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Subjects ( men woman ) age Â³ 18 Patients undergoing elective coronary stenting ( 200 patient ) STsegment elevation myocardial infarction within 48 hour prior randomization Prior PCI within previous 4 week randomization plan stag PCI within subsequent month . Cardiogenic shock &gt; 50 % unprotected leave main stenosis Any low molecular weight heparin within prior 12 hour Treatment P2Y12 blocker ( Plavix Ticlid ) within previous 14 day randomization Treatment platelet GPIIb/IIIa inhibitor within previous 30 day randomization Concurrent treatment warfarin History bleeding diathesis , evidence active abnormal bleeding within 30 day randomization . History hemorrhagic stroke time , stroke TIA etiology within 30 day randomization . Major surgery within 6 week prior randomization . Known platelet count &lt; 100,000/mm3 . PT &gt; 1.5 X control HCT &lt; 25 % Known allergy contraindication eptifibatide , heparin , aspirin plavix . Participation study experimental therapy device 30 day prior randomization . Creatinine level great 2.0 mg/dl creatinine clearance &lt; 30mL Known history alcohol drug abuse Pregnant woman woman child bear potential use acceptable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>